COMMUNIQUÉS West-GlobeNewswire

PhaseBio To Report Third Quarter 2018 Financial and Business Results on November 29, 2018
21/11/2018
MALVERN, Pa. and SAN DIEGO, Nov. 21, 2018 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies [...]
VBL Therapeutics to Present at the Piper Jaffray 30th Annual Healthcare Conference on November 28
21/11/2018
TEL AVIV, Israel, Nov. 21, 2018 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for [...]
Abattis Retains Canadian and American Compliance Agency and Provides Company Update
21/11/2018
VANCOUVER, British Columbia, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Abattis Bioceuticals Corp (the “ Company ” or “ Abattis ”) (CSE:ATT) (OTC:ATTBF) is pleased to announce the appointment of Ingredient Identity LLC (“ [...]
BioSyent Releases Results for Third Quarter and First Nine Months of 2018
21/11/2018
TORONTO, Nov. 21, 2018 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and nine months ended September 30, 2018. Key highlights include: [...]
Nexstim Plc's resolutions of the Extraordinary General Meeting of Shareholders
21/11/2018
Company announcement, Helsinki, 21 November 2018 at 2:00 PM Nexstim Plc's resolutions of the Extraordinary General Meeting of Shareholders Nexstim Plc (NXTMH:HEX, NXTMS:STO), the targeted neuromodulation company [...]
CureVac to Present at the 19th Annual Piper Jaffray Healthcare Conference
21/11/2018
TÜBINGEN, Germany and BOSTON, Nov. 21, 2018 (GLOBE NEWSWIRE) -- CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced that Dan Menichella, Chief Executive [...]
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
21/11/2018
ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 21, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, [...]
Aleafia and Serruya Private Equity Reach Agreement for National Retail Dispensary, top Performing Brands and $10M Investment
21/11/2018
Transactions Positions Aleafia as Major Supplier, Retailer of Adult-use Cannabis TORONTO, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSXV: ALEF; OTCQX: ALEAF, FRA: ARAH) (“Aleafia“ or the “Company“), and [...]
Clementia to Present at the Evercore ISI HealthCONx Conference
21/11/2018
MONTREAL, Nov. 21, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (Nasdaq: CMTA), a clinical-stage biopharmaceutical company innovating treatments for people with ultra-rare bone disorders and other diseases, [...]
Clementia annonce qu’elle participera à la Conférence Evercore ISI HealthCONx (« Evercore ISI HealthCONx Conference »)
21/11/2018
MONTRÉAL, 21 nov. 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc . (Nasdaq: CMTA), une société biopharmaceutique au stade clinique proposant des traitements novateurs pour les personnes atteintes de troubles [...]
HEXO Announces Filing Of Final Base Shelf Prospectus
21/11/2018
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES GATINEAU, Quebec, Nov. 21, 2018 (GLOBE NEWSWIRE) -- HEXO Corp. (“ HEXO ” or the “ Company ”) (TSX:HEXO) announced that it has [...]
HEXO annonce le dépôt d’un prospectus préalable de base définitif
21/11/2018
NE PAS DISTRIBUER AUX FILS DE PRESSE AMÉRICAINS ET NE PAS PUBLIER AUX ÉTATS-UNIS. GATINEAU, Québec, 21 nov. 2018 (GLOBE NEWSWIRE) -- HEXO Corp. (« HEXO » ou la « Société ») (TSX: HEXO) a annoncé le dépôt d’un prospectus [...]
OraSure Technologies to Present at the 30th Annual Piper Jaffray Healthcare Conference
21/11/2018
BETHLEHEM, Pa., Nov. 21, 2018 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR), a leader in point of care diagnostic tests and specimen collection devices, today announced that Stephen S. Tang, Ph.D., [...]
Eckert & Ziegler BEBIG: Convening Notice of the Extraordinary General Meeting of Shareholders
21/11/2018
CONVENING NOTICE OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Eckert & Ziegler BEBIG Limited Liability Company offering its securities to the public Industrial Zone C, 7180 Seneffe VAT BE 457.288.682 [...]
Eckert & Ziegler BEBIG: Convocation à l'assemblée générale extraordinaire des actionnaires
21/11/2018
CONVOCATION A L'ASSEMBLEE GENERALE EXTRAORDINAIRE DES ACTIONNAIRES Eckert & Ziegler BEBIG Société anonyme ayant fait appel public à l'épargne Zone Industrielle C, 7180 Seneffe TVA BE 457.288.682 Registre des [...]
TLC Announces Pricing of Initial Public Offering of American Depositary Shares (ADSs) on Nasdaq
21/11/2018
TAIPEI, Taiwan and SOUTH SAN FRANCISCO, Calif., Nov. 21, 2018 (GLOBE NEWSWIRE) -- Taiwan Liposome Company, Ltd. (4152.TWO) (TLC), a clinical-stage specialty pharmaceutical company dedicated to the development and [...]
The Phase III study protocol is modified after IBT’s meeting with the FDA
21/11/2018
The Phase III study protocol is modified after IBT’s meeting with the FDA Yesterday afternoon (EST) Infant Bacterial Therapeutics had a meeting with the US Food and Drug Administration (FDA) in Washington DC to discuss [...]
LIDDS adds two major university clinics in Lithuania to speed up enrollment in ongoing Phase IIb study
21/11/2018
The National Cancer Institute in Vilnius and the University Clinic of Kaunas are now ready to start inclusion of patients in Part II of the LPC-004 study. Lithuanian authorities have recently approved the study protocol [...]
UPDATE - BriaCell to Present Updated Clinical Data Including Early Safety Data in KEYTRUDA® Combination Study and Positive Phase IIa Monotherapy Efficacy Data at 2018 San Antonio Breast Cancer Symposium
21/11/2018
Note: This Press Release contains amendments to the press release previously issued on Nov. 19, 2018 Positive proof of concept data with Bria-IMT™ Monotherapy will highlight potent anti-tumor activity and an excellent [...]

Pages